Skip to content


  • Meeting abstract
  • Open Access

Phenotype of regulatory T cells in human type 1 diabetes at diagnosis and partial remission phase

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • ,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1Email author
Diabetology & Metabolic Syndrome20157 (Suppl 1) :A208

  • Published:


  • Beta Cell
  • Partial Remission
  • Insulin Dose
  • Pancreatic Beta Cell
  • Human Type


Human type 1A diabetes (T1AD) has a broad spectrum of clinical presentations, which may be associated with the severity of autoimmune response and consequently, different levels of pancreatic beta cells destruction. The T1AD presents a partial remission phase. The remission phase is classically a short period in childhood-onset diabetes, but longer periods may occur especially in young.


This study was designed to investigate cellular immunity focusing regulatory T-cells (Tregs) in different disease stages of the disease.

Materials and methods

A total of 13 T1AD patients: 8 newly-diagnosed T1AD (age: 7.9±6.3 yrs., insulin dose: 0.5 U/kg/day) within 1.0±0.9 months of their diagnosis, 5 in partial remission, for 1.2±1.0 yrs. after diagnosis (age: 10.8±6.8 yrs., insulin dose: 0.2 U/kg/day) and 9 healthy controls (21.9±2.7yrs.) were studied. Phenotypic analysis of Tregs was performed by flow cytometry on peripheral blood. After a Lyse/Wash protocol, cells were stained for CD4, FoxP3, CTLA4, CD25. T cell markers CD25, CTLA-4 and FoxP3 were examined on cells within the CD4 gate. Groups were compared using an one-way ANOVA test.


The frequency of circulating CD4+CD25+ and CD4+FoxP3+ T cells was significantly reduced in newly-diagnosed T1AD compared to patients in partial remission and controls (1.7±0.6% vs 4.0±2.1% vs 3.3±1.2%, p<0.01 and 0.7±0.7% vs 2.0±2.0% vs 2.3±0.8%, p<0.03 respectively).


These preliminary data showed decreased peripheral Tregs frequency in classical childhood-onset T1AD. In contrast, the group of long-term remission patients had similar frequency to controls and some of them presented latent autoimmune diabetes features. Immunophenotyping at the time of diagnosis and during follow-up may help the definition of both T1AD clinical subtypes and remission period.

Authors’ Affiliations



© da Silva Camilo et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.